ArticleBMC women's health2025
Association between osteoporosis and severe depressive symptoms among postmenopausal women attending tertiary outpatient clinics in Nigeria: a cross-sectional study.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesOsteoporosis and depression are significant, frequently co-occurring conditions in postmenopausal women, particularly in low- and middle-income countries where access to integrated care is limited. This study aimed to examine the association between osteoporosis and severe depressive symptoms among postmenopausal women attending tertiary outpatient clinics in Nigeria and to identify related demographic, clinical, and lifestyle correlates.
methodsA hospital-based cross-sectional survey was conducted from July 2024 to May 2025 across 12 purposively selected tertiary outpatient clinics representing all six geopolitical zones of Nigeria. A total of 712 postmenopausal women aged ≥ 45 years (mean age: 60.3 years) were recruited using multistage and convenience sampling. Data were collected via a validated, structured questionnaire; the Osteoporosis and Depression Assessment Questionnaire (ODAQ), which included sociodemographic data, menopausal and clinical history, osteoporosis risk factors, PHQ-9 depression screening, and lifestyle variables. Descriptive statistics and chi-square (χ²) tests were used to analyze the association between osteoporosis and depressive symptoms, with significance set at p ≤ 0.05.
resultsSevere depressive symptoms were identified in 75.6% of participants. Depression was significantly more common among those with osteoporosis (79.1% vs. 66.5%; χ² = 2.190, p = 0.010) and a history of fractures (87.1% vs. 68.2%; χ² = 5.513, p = 0.012). Other factors associated with higher depressive symptoms included older age (≥ 60 years), late menopause (after age 50), low parity (≤ 5 pregnancies), comorbid chronic conditions (80.4%; p = 0.031), and abnormal anthropometry. Adequate calcium intake was associated with lower depression rates (61.1% vs. 80.9%; p = 0.010). Notably, non-smokers and alcohol users exhibited higher depression rates compared to their counterparts, suggesting possible coping behaviors or reporting biases.
conclusionThe findings underscore a strong association between osteoporosis and severe depressive symptoms in Nigerian postmenopausal women, highlighting the urgent need for integrated mental and bone health interventions in tertiary and primary healthcare settings. Screening for depression should be routinely included in osteoporosis management to improve outcomes in aging women. This study supports WHO’s call for integrated non-communicable disease care and offers evidence to inform policy and clinical practice in similar low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.